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Abstract
Background: Linear Array Genotyping Test (LA) is one of the gold standards used for Human Papillomavirus (HPV)
genotyping, however, since its launching in 2006, new HPV genotypes are still being characterized with the use of
high specificity techniques such as Next-Generation Sequencing (NGS). Derived from a previous study of the IMSS
Research Network on HPV, which suggested that there might be cross-reaction of some HPV genotypes in the LA
test, the aim of this study was to elucidate this point.
Methods: Double stranded L1 fragments (gBlocks) from different HPVs were used to perform LA test, additionally,
14 HPV83+ and 26 HPV84+ cervical samples determined with LA, were individually genotyped by NGS.
Results: From the LA HPV83+ samples, 64.3% were truly HPV83+, while 42.9% were found to be HPV102+. On the
other hand, 69.2% of the LA HPV84+ samples were HPV84+, while 3.8, 11.5 and 30.8% of the samples were indeed
HPV 86, 87 and 114 positive, respectively. Additionally, novel nucleotide changes in L1 gene from HPV genotypes
83, 84, 87, 102 and 114 were determined in Mexican cervical samples, some of them lead to changes in the protein
sequence.
Conclusions: We demonstrated that there is cross-hybridization between alpha3-HPV genotypes 86, 87 and 114
with HPV84 probe in LA strips and between HPV102 with HPV83 probe; this may be causing over or under
estimation in the prevalence of these genotypes. In the upcoming years, a switch to more specific and sensitive
genotyping methods that detect a broader spectrum of HPV genotypes needs to be implemented.
Keywords: Cervical samples, HPV, L1 mutations, Linear Array HPV Genotyping Test, Next-Generation Sequencing,
Cross-hybridization
Background
Human Papillomaviruses (HPV) belong to a diverse
group of small non-encapsulated dsDNA viruses that
have evolved over millions of years [1]. HPV classifica-
tion and nomenclature is defined by the International
Committee for the Taxonomy of Viruses (ICTV) and the
HPVs described to date are classified in different genera
and species based on L1 gene sequence percentages of
identity [2]. HPVs belong to five different genera called
Alpha-, Beta-, Gamma-, Mu- and Nu-PVs [3]. Each HPV
is adapted to infect a specific epithelial tissue such as
skin or mucosa, and most of them do not cause an
apparent pathology and are cleared in some months
or years. However, some Alpha HPV genotypes are
medically relevant because of their carcinogenic poten-
tial if the infection persists over the years. According to
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the International Agency for Research on Cancer (IARC),
12 HPV genotypes are defined as oncogenic or high-risk
(HR-HPVs): 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and
59. Some other genotypes are possibly carcinogenic while
most of the remaining viruses are non-carcinogenic or
low-risk (LR-HPV) [2, 4]. HPV16, the most prevalent
genotype worldwide, is found in around 60% of cervical
cancer samples according to a meta-analysis performed in
115,789 HPV-positive women, followed by HPV18 and
HPV45 [5].
Cervical cancer (CC) is the most common HPV-re-
lated cancer and consequently HR-HPVs are widely
studied to better understand and treat HPV-driven cer-
vical carcinogenesis. However, there are not so many
studies on LR-HPVs and HPV coinfections, which could
unravel important information on their role in either
carcinogenesis or viral clearance. In industrialized coun-
tries, CC screening is performed with three main
methods: cytology, DNA or RNA detection of HR-HPVs
or cytology-HPV co-testing [4]. HPV genotyping tests
are widely used worldwide in many laboratories and
there is an increased need to develop reliable and
cheaper tests that detect most of the high and low-risk
HPVs described to date. The Linear Array Genotyping
test from Roche (LA), launched in 2006, allows the de-
tection of 37 HPV genotypes (6, 11, 16 18, 26, 31, 33, 35,
39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64,
66, 67, 68, 69, 70, 71, 72, 73 (MM9), 81, 82 (MM4), 83
(MM7), 84 (MM8), IS39, and CP6108) and is one of the
gold standards used for genotyping [6–8]. Moreover,
while new HPV genotypes are still being character-
ized, the use of high-throughput screening technolo-
gies such as Next-Generation Sequencing (NGS),
allows genotyping of a broader spectrum of HPVs
when compared to the commercially available tests.
In a previous study of our research group, LA and
454 NGS were performed in cervical samples from
Mexican women. In some of the samples, not all
HPV genotypes detected with LA were confirmed by
NGS (indicating the possible non-specific detection of
the LA), whereas five HPVs that cannot be detected
with the LA test were detected by NGS: 32, 44, 74,
102 and 114 [9]. This finding suggested that there
could be a cross-reaction between those HPVs not in-
cluded in LA and the probes of the test.
The aim of the present study was to determine how
specific is the worldwide used LA test, by looking at
a possible cross-hybridization in the LA strips and to
estimate the frequency of the HPVs that could cross-
react. In this work, mutations in the PGMY11/09
amplified L1 gene fragment from the HPV genotypes
that cross-hybridized in LA test were described, to
see if new variants or subtypes of those HPVs could
be infecting the Mexican population.
Methods
Sample collection
In the present study, cervical samples were collected
from women who attended a medical examination at the
Dysplasia Clinic - Centro Médico Nacional de Occidente
(CMNO-IMSS) in Guadalajara, Jalisco, Mexico; and
from diverse Hospitals around Mexico as previously
published [9, 10]. The sample recruitment was done
from 2014 to 2017 by gynecologists, with a cytobrush
inserted into the endocervical canal. From those sam-
ples, 535 were positive to HPV by using Linear Array
Genotyping Test.
HPV genotyping by Linear Array
Total DNA was extracted from cervical samples collected
in Preserv-Cyt medium solution (Cat. no. 70097-002,
Hologic, Inc., Marlborough, MA, USA) and purified using
the AmpliLute Liquid Media Extraction Amplicor kit
(Cat. no. 03750540190; Roche Molecular Systems, Inc.,
Branchburg, NJ, USA.) following the manufacturer in-
structions. All samples were genotyped by Linear Array
HPV Genotyping Test (Cat. no. 03378179190, Roche
Molecular Systems) as previously described [9].
Linear Array test using L1 gBlocks
Double stranded genomic blocks (gBlocks) were de-
signed by choosing the PGMY11/09 amplified L1 se-
quences from HPV reference genotypes 32 (X74475), 44
(U31788), 74 (AF436130), 86 (AF349909), 87 (AJ400628),
102 (DQ080083) and 114 (GQ244463), and were synthe-
tized by IDT (Integrated DNA Technologies, Coralvillle,
Iowa, USA). The gBlocks were resuspended in 1X TE, and
subsequently 10 pg of each specific gBlock were taken to
proceed with LA.
Next-generation sequencing
The positive samples to HPV83 and HPV84 determined
by LA that showed a clear hybridization band in the
HPV strips, were selected to perform NGS. First, the
DNA of each sample was amplified by conventional PCR
with the PGMY primers [11]. Then, a second PCR reac-
tion was performed using the same primers coupled to a
universal tail sequence, as previously described [9].
Briefly, the PCR products were quantified with the fluor-
ometry assay Qubit dsDNA HS (Cat. no. Q32854, Life
Technologies, Eugene, OR, USA), subsequently, each
sample was diluted to 5x109 molecules per microliter.
Then, individual barcodes were added to each sample
using the 454 MIDs from Multiplicom NV CFTR kits
(Cat. no. ML-0008.192, ML-0016.192 and ML-0124.192,
Molecular Diagnostics, Niel, Belgium). Each sample was
purified with the Agentcourt AMPure XP beads (Cat.
no. A63880, Beckam Coulter Genomics, Danvers, MA,
USA) and evaluated with the Agilent DNA 1000 kit
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(Cat. no. 5067-1504, Agilent Technologies, Santa Clara,
CA, USA) on the 2100 Bionalyzer (Cat. no. G2939BA,
Agilent Technologies). For sequencing, GS Junior Titan-
ium kits were used in a GS Junior Sequencer, following
the manufacturer’s instructions (Cat. no. 05996562001,
05996589001, 05996597001, 05996619001, Roche Diag-
nostics, Basel, Switzerland).
Data analysis
The sequencing data were first analyzed with the FastQC
tool to determine the quality of the sequences [12].
Then, to identify specific HPV genotype sequences
present in each cervical sample, the Roche GS Reference
Mapper v3.0 software was used, taking as references all
the L1 sequences reported in the Papillomavirus Episteme
(PaVE) database [13]. The parameters considered for map-
ping were the following: trimming of adapters and
primers, 90% of minimum overlap identity, Phred score ≥
20, minimum read length of 100 bp and exclusion of all
the repeated reads. All HPV raw sequence reads were
uploaded in the NCBI Sequence Read Archive (accession
number SRP130362).
Among the nucleotide changes observed in the L1
gene from HPVs 83 (AF151983), 84 (AF293960), 86
(AF349909), 87 (AJ400628), 102 (DQ080083) and 114
(GQ244463), we described those that were present in all
the reads from a specific HPV with a minimum depth of
20 reads or those found in two or more distinct samples
(independently of the reads number).
Finally, a phylogenetic tree was constructed with L1
consensus sequences from HPV83, 84, 86, 87, 102 and
114 from each sample, including the L1 reference se-
quences from all alpha3-papillomaviruses. Evolutionary
analyses were conducted in MEGA 7 software by using
the muscle algorithm for the alignment of sequences
and the evolutionary history was inferred by using the
Maximum Likelihood method based on the Tamura-Nei
model [14, 15]. All positions with less than 95% site
coverage were eliminated and the tree with the highest
log likelihood was chosen.
Results
Cross-hybridization between HPV genotypes in Linear
Array Genotyping test
Previous results of our working group showed that in
some cervical samples, not all HPV genotypes detected
with LA were found by NGS; in contrast, other geno-
types such as 32, 44, 74, 102 and 114 were detected only
with NGS. These findings suggested that positivity to
some HPVs in LA could be due to the presence of other
genotypes not included in the test. To see if there is a
cross-reaction between HPVs 32, 44, 74, 102 and 114
(not included in the LA test) with any probe of the LA
strip, amplification and hybridization was performed
Fig. 1 Linear array Genotyping test performed individually with different L1 gBlocks (double stranded genomic blocks). The gBlocks were designed
from HPV genotypes 102 (a), 114 (b), 86 (c) and 87 (d) and taken as template for the LA test
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using as template the gBlocks of an L1 fragment from
each of those HPVs. HPV32, 44 and 74 did not
cross-hybridize with any of the HPV probes included in
LA test (data not shown). However, L1 gBlocks from
alpha-3 HPV102 and HPV114 cross-linked with HPV83
and HPV84 probes, respectively (Fig. 1a and b). Since
also HPVs 86 and 87 are alpha-3 genotypes not included
in LA, the test was therefore performed additionally with
HPV86-L1 and HPV87-L1 gBlocks. Both HPVs showed
cross-reactivity with HPV84 (Fig. 1c and d).
Next-generation sequencing of HPV83 and HPV84
positive samples
From a total of 535 cervical samples genotyped by LA,
16 were HPV83+ (3.0%) and 35 were HPV84+ (6.5%).
As HPV83 and HPV84 probes in LA strips cross-
hybridize with L1 gBlocks from other genotypes, we se-
lected 14 HPV83+ (S9, S27-S39) and 26 HPV84+
(S1-S26) samples (based on their strong hybridization
band in the LA strips) to be genotyped by NGS individu-
ally. As depicted in Table 1, HPV genotyping by NGS
showed that from the 26 cervical samples LA HPV84+,
17 were truly HPV84+ (65.4%), 5 were HPV114+
(19.2%), and 1 was HPV86+ (3.8%). Additionally, 2 sam-
ples were positive to both HPV 87 and 114, and finally 1
was HPV 84, 87 and 114 positive. HPV87 was found in
the three cases in coinfection with HPV114. Concerning
the 14 cervical samples LA HPV83+, 8 were truly
HPV83+ (57.1%), 5 were HPV102+ (35.7%) and 1 was
positive to both genotypes (Table 2).
L1 gene mutations from HPV83, 84, 87, 102 and 114
After comparing the sequences obtained by NGS with
the L1 reference genes (downloaded from PaVE data-
base), nucleotide variations in L1 fragment from HPV
genotypes 83, 84, 87, 102 and 114 were determined.
Concerning HPV83-L1, only sample S27 contained an
L1 gene fragment identical to the reference, and rest of
the samples showed diverse synonymous mutations. The
most common nucleotide changes were c.1200A>G (in 6
samples), c.1191A>G (in 5 samples), c.1227G>C (in 5
samples), and c.1008A>G (in 4 samples) (Table 3). Re-
garding HPV84-L1, seventeen out of eighteen samples
showed one or more nucleotide changes, being the
non-synonymous mutation c.1323C>A (p.D441E) the
most prevalent one (in 16 samples). Another HPV84-L1
non-synonymous mutation was detected in only one
sample: c.1055A>C (p.N352T) (Table 4). Additionally,
Table 1 HPV genotyping by NGS of 26 cervical samples LA
HPV84+
Sample Number Linear Array NGS
S1 39, 51, 56, 58, 62, 84 39, 51, 58, 62, 84
S2 45, 59, 66, 73, 84, 89 45, 59, 66, 73, 89, 114
S3 6, 53, 61, 84, 89 6, 53, 61, 84, 89
S4 16, 42, 45, 54, 84 16, 69, 84
S5 31, 56, 66, 82, 84 56, 84
S6 58, 81, 82, 84, 89 16, 44, 53, 58, 66, 72, 81,
82, 84, 89
S7 11, 42, 61, 84 11, 61, 114
S8 16, 51, 54, 84 16, 54, 84
S9 16, 53, 83, 84 16, 53, 62, 83, 114
S10 16, 61, 84, 89 16, 61, 83, 84, 89
S11 35, 66, 84, 89 32, 35, 66, 84, 89
S12 39, 54, 61, 84 39, 51, 54, 58, 61, 62,
84, 87, 106, 114
S13 39, 61, 84, 89 61, 89, 87, 114
S14 56, 66, 70, 84 16, 66, 70, 87, 114
S15 69, 71, 81, 84 69, 71, 81, 114
S16 11, 39, 84 11, 39, 114
S17 45, 62, 84 45, 62, 84
S18 56, 61, 84 6, 56, 61, 68, 84
S19 16, 84 16, 70, 81, 83, 86
S20 18, 84 18, 84
S21 31, 84 31, 83, 84
S22 31, 84 31, 54, 84
S23 45, 84 45, 84
S24 45, 84 45, 66, 84
S25 59, 84 59, 84
S26 66, 84 66, 84
The first column shows LA results and the second column NGS results. HPV84,
86, 87 and 114 are darkened for an easier visualization
Table 2 HPV genotyping by NGS of 14 cervical samples LA
HPV83+
Sample Number Linear Array NGS
S27 16, 42, 58, 62, 81, 83 16, 58, 81, 83
S28 51, 54, 58, 66, 83, 89 58, 66, 83, 89
S29 11, 52, 59, 62, 83 11, 52, 59, 62, 83
S30 35, 54, 70, 83, 89 35, 54, 70, 89, 102
S31 54, 55, 61, 83, 89 61, 89, 102
S32 11, 62, 70, 83 16, 61, 62, 70, 83, 89
S9 16, 53, 83, 84 16, 53, 83, 114
S33 31, 62, 72, 83 31, 72, 102
S34 45, 59, 64, 83 52, 56, 59, 61, 71, 74, 102
S35 52, 61, 71, 83 52, 61, 71, 56, 74, 102
S36 31, 61, 83 31, 61, 83
S37 52, 81, 83 52, 81, 83
S38 51, 83 51, 61, 83, 102
S39 83 83, 81
The first column shows LA results and the second column NGS results. HPV83
and 102 are darkened for an easier visualization
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two L1 synonymous mutations were found in the three
HPV87+ samples: c.1056T>C and c.1359A>G. About
HPV102-L1 nucleotide changes, three out of the six posi-
tive samples (S30, S34 and S35) showed c.1362A>G muta-
tion in their L1 sequence and only S30 sample showed the
non-synonymous mutation c.1060G>A (p.G354S). Among
the eight HPV114+ samples, nine mutations were detected,
three of them present in all the HPV114-L1 sequences:
c.1318C>G (p.P440A), c.1332A>G and c.1359C>T. Further-
more, two non-synonymous mutations were found in four
samples: c.1297T>A (p.S433T) and c.1331C>A (p.T444K)
(Table 5). Finally, no HPV86-L1 mutations were detected.
To visualize the relationship between the reference
alpha-3 HPV genotypes and those obtained from the
Mexican cervical samples (HPV83, 84, 86, 87, 102, 114),
a phylogenetic tree was built based on their L1 gene se-
quences (Fig. 2).
Discussion
During the last decade, cytology-based screening is being
replaced with HPV genotyping; Linear Array genotyping
test is commonly used in many laboratories for HPV de-
tection [8, 16]. LA test, launched in 2006, is a PCR-
based strategy with pooled primer sets, coupled to
hybridization to specific probes for 37 anogenital HPV
genotypes immobilized on a nylon strip [7]. This test has
the most abundant data in peer-reviewed literature clas-
sifying it as one of the most frequently used [17]. Un-
doubtedly, LA is a sensitive test of great value for
epidemiological studies and HPV genotyping, but more
sensitive, specific and accurate methods such as NGS
allow the identification of not only a broader spectrum
of HPVs, but also subtypes and variants [18–20].
HPV84 was characterized as a novel genotype in 2001
by M. Terai and R. D. Burk (accession number AF293960)
from a cervicovaginal sample obtained from a 21-year-old
Caucasian female with a normal Pap smear [21]. It is con-
sidered as a LR-HPV and is among the most prevalent
LR-HPVs found worldwide in cervical samples [22–30].
Both HPV83 and HPV84 belong to the Alphapapilloma-
virus genus, species 3 group (alpha-3) together with HPV
61, 62, 72, 81, 86, 87, 89, 102 and 114. From these geno-
types, only 102 and 114 were characterized after LA test
was launched [31, 32], and are obviously not included in
the test, neither do HPV86 and HPV87.
In the present study, non-specific hybridization of four
alpha-3 HPVs in the LA test, the golden test used to de-
tect HPVs in a patient’s sample, is being reported.
Indeed, HPV102-L1 cross-reacts with the probe that
Table 3 Nucleotide changes identified in HPV83-L1 when compared to the reference sequence (AF151983) in nine HPV83+ samples
Sample number c.1008
A > G
c.1104
A > C
c.1152
G > T
c.1170
A > C
c.1191
A > G
c.1200
A > G
c.1227
G > C
c.1227
G > A
c.1233
C > T
c.1264
C > T
S9 ● ● ● ●
S27
S28 ● ●
S29 ● ● ● ●
S32 ● ●
S36 ● ● ● ● ● ●
S37 ● ● ● ●
S38 ● ● ●
S39 ● ● ● ●
Table 4 Nucleotide changes identified in HPV84-L1 when
compared to the reference sequence (AF293960) in eighteen
HPV84+ samples
Sample number c.1011
A > G
c.1055
A > Ca
c.1173
C > A
c.1323
C > Aa
S1 ●
S3 ●
S4
S5 ●
S6 ●
S8 ●
S10 ●
S11 ●
S12 ●
S17 ●
S18 ● ●
S20 ● ●
S21 ●
S22 ●
S23 ●
S24 ●
S25 ● ●
S26 ● ●
anon-synonymous nucleotide changes
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detects HPV83, and likewise, HPV genotypes 86, 87 and
114 cross-react with the probe that detects HPV84.
These results explain the observations in a previous
study where we reported that not all HPV genotypes de-
tected in some cervical samples with LA test were con-
firmed by NGS (like HPV83 and HPV84), whereas five
HPVs not included in LA were detected by NGS (HPVs
32, 44, 74, 102 and 114) [9]. With the current study, we
reveal that what happened in the previous work was that
positivity to HPV83 and HPV84 in the LA test was only
true in the 57.1% and 65.4% of the cases, respectively. In
addition, as LA test is sometimes showing positivity to
HPVs 83 and 84 when they are not present in the sam-
ple, the prevalence of these genotypes could be over-
rated, as discussed later. Moreover, we cannot dismiss
the possibility that more HPV genotypes from other spe-
cies could also cross-react with some of the probes in
the LA strip. An already reported limitation of LA is
that additional testing is necessary to detect the
HR-HPV52 when HPVs 33, 35 and/or 58 are present in
the sample [33]. However, to our knowledge, this is the
first report proving a cross-hybridization in LA test.
In this work, HPV genotyping by NGS of HPV84 posi-
tive samples (detected by LA), revealed that 69.2% of the
samples were truly HPV84+, while 30.8% were HPV114
+, 3.8% were HPV86+ and 11.5% were HPV87+. It is im-
portant to mention that some samples were coinfected
with more than one of these genotypes. On the other
hand, among HPV83+ samples with LA, 64.3% were
confirmed as HPV83+ with NGS, while 42.9% were
HPV102+. A recent publication shows that the clinical
performance of the LA test within the VALGENT-3
framework, which is designed for comprehensive com-
parison and clinical validation of HPV tests, is accurate
for primary cervical cancer screening [34]. Nevertheless,
another recent genotyping study that compares ion
torrent-next generation sequencing vs. linear array to
detect anal HPVs in individual clinical specimens shows
that the NGS assay detects 10 HPV genotypes that are
not among the ones detected in LA test: 30, 32, 43, 44,
74, 86, 87, 90, 91, 114 [35]. Some of these HPVs could
be cross-reacting with LA test as we demonstrated in
this work.
New HPV genotyping tests must be developed in the
upcoming years since an increasing number of geno-
types are being described by using NGS platform, and
their prevalence and role in cervical lesion progression
needs to be assessed. Indeed, 105 putative new papillo-
mavirus types have been identified by using a novel
protocol based on improved PCR protocols combined
with NGS [36]. Moreover, HPV coinfections could be
hiding essential information on cervical lesion pro-
gression and more meticulous studies on multiple in-
fections are also necessary in the near future for
understanding the link between coinfections and
carcinogenesis. Furthermore, FAP primers based se-
quencing is sensitive and effective for detection of cu-
taneous HPVs and its use in cervical samples could
contribute to a broader knowledge on HPV infections
in cervical mucosa [37–39].
The L1 gene is used for the classification of HPV ge-
notypes as it is well conserved among all of them. HPV
genotypes share between 71 and 89% of nucleotide iden-
tity, and within the same HPV type, HPV variants can
be described [40, 41]. After HPV genotyping by NGS,
new nucleotide changes in PGMY amplified L1 sequence
have been described in this work for HPV genotypes 83,
84, 87, 102 and 114. From all the nucleotide changes re-
ported here, HPV84-L1, HPV102-L1 and HPV114-L1
have two, one and three non-synonymous mutations, re-
spectively. To our knowledge, there is only one study
that also describes one of the nucleotide changes re-
ported in this work: c.1323C>A in HPV84-L1 [42]. Fur-
ther functional analysis should be done to understand
the biological significance of the amino acid changes.
Conclusions
This study showed that HPV genotypes 86, 87 and 114
cross-hybridize with HPV84 in LA test and that HPV102
cross-reacts with HPV83 probe; these observations were
Table 5 Nucleotide changes identified in HPV114-L1 when compared to the reference sequence (GQ244463) in eight HPV114+ samples
Sample number c.1059
C > T
c.1167
A > C
c.1297
T > Aa
c.1299
C > A
c.1305
G > A
c.1318
C > Ga
c.1331
C > Aa
c.1332
A > G
c.1359
C > T
S2 ● ● ● ● ● ●
S7 ● ● ● ● ● ●
S9 ● ● ● ● ● ●
S12 ● ● ● ● ●
S13 ● ● ● ● ● ●
S14 ● ● ● ● ●
S15 ● ● ● ● ●
S16 ● ● ●
anon-synonymous nucleotide changes
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confirmed by comparing LA genotyping with NGS data.
Therefore, there is an over estimation of HPV 83 and 84
prevalence when HPV genotyping is performed with LA.
On the other hand, it would be important to determine
the prevalence and role in carcinogenesis of HPVs 86, 87,
102 and 114. Novel nucleotide changes in L1 gene from
HPVs 83, 84, 87, 102 and 114 were determined in Mexican
cervical samples, some of them lead to changes in the pro-
tein sequence. The biological significance of those changes
should be determined in the near future. There is no
doubt that more specific and sensitive tests to detect a
broader spectrum of HPV genotypes should be imple-
mented in the clinical practice.
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Fig. 2 Phylogenetic tree based on alpha-3 HPVs L1 sequences. The
analysis involved the 11 reference HPVs from alpha-3 species (REF)
and 39 L1 sequences from HPVs 83, 84, 86, 87, 102 and 114 that infect
Mexican woman. The tree is drawn to scale, with branch lengths
measured in the number of substitutions per site
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